Trials / Completed
CompletedNCT05924152
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adagrasib | Adagrasib |
| DRUG | Eltrombopag + adagrasib | Eltrombopag + adagrasib |
Timeline
- Start date
- 2023-06-29
- Primary completion
- 2023-08-09
- Completion
- 2023-08-17
- First posted
- 2023-06-29
- Last updated
- 2024-03-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05924152. Inclusion in this directory is not an endorsement.